Hatteras Venture Partners

Hatteras Venture Partners is a North Carolina-based venture capital firm that finances biomedical companies.

Business Model:

Revenue: $6.1M

Employees: 2-10

Rankings

Detailed Hatteras Venture Partners Information

Geographic Data

Hatteras Venture Partners headquarters map

Address: 280 S Mangum St

City: Durham

State: NC

Zip: 27701

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$598M

Metrics

3,379,412Website Global Rank

3,884Website Monthly Traffic

Twitter Followers

Description

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Contact Phone:
+19194840730

Contact Email:

Announced Date Company Transaction Money Raised
10/2015 Qvella Corporation Series A 20M
2/2017 Artizan Biosciences Venture Round -
6/2017 StrideBio Seed Round -
1/2021 Myeloid Therapeutics Series A 50M
1/2012 GeneCentric Therapeutics Seed Round -
1/2012 Clearside Biomedical Series A 4M
1/2021 NoviSci Seed Round -
1/2011 TetraLogic Pharmaceuticals Series C 0
10/2014 Viamet Pharma Series D 60M
6/2012 PhaseBio Pharmaceuticals Series B 23M
12/2018 WalletFi Convertible Note 0
10/2018 Qpex Biopharma Series A 33M
7/2009 Viamet Pharmaceuticals Series B 25M
4/2020 Atsena Therapeutics Venture Round 8.2M
3/2017 Boragen Series A 10M
8/2020 Qvella Corporation Venture Round -
3/2016 Bivarus Series A 0
11/2018 Kymera Therapeutics Series B 65M
9/2021 Elligo Health Research Series E 0
3/2017 HistoSonics Series B 0
2/2010 HistoSonics Series A 0
5/2014 Jumo Health Series B 0
11/2021 GeneCentric Therapeutics Series B 0
1/2010 PhaseBio Pharmaceuticals Series B 25M
9/2021 Qvella Corporation Venture Round -
1/2008 Clinipace Series B 0
10/2021 GoCheck Venture Round 0
5/2015 Nusirt Series C 0
4/2015 Contego Medical Series B 0
8/2014 Clinverse Series C 9.1M
12/2013 Curoverse Seed Round 1.5M
6/2018 StrideBio Series A 15.7M
11/2022 410 Medical Series B 0
5/2015 Spyryx Biosciences Series A 18.2M
6/2008 SpineAlign Medical Unattributed 8.8M
5/2019 Elligo Health Research Series C 0
5/2023 Ten63 Therapeutics Series A 0
4/2023 Mercy BioAnalytics Series A 0
11/2022 Boomerang Medical Series A 0
4/2020 AtaCor Medical Series B 0
1/2017 Trefoil Therapeutics Series A 0
8/2019 GrayBug Series C 80M
8/2021 Vigil Neuroscience Series B 0
1/2022 AN2 Therapeutics Series B 80M
12/2021 Tune Therapeutics Series A 40M
10/2008 Pathfinder Therapeutics Series A 0
5/2016 GrayBug Series B 44.5M
9/2011 Clinipace Series C 15M
6/2007 Viamet Pharmaceuticals Series A 4M
3/2015 PhaseBio Pharmaceuticals Series C 0
6/2008 ArtusLabs Series A 0
9/2017 Rodin Therapeutics Series C 0
2/2015 Lysosomal Therapeutics Series A 20M
11/2018 Ribometrix Series A 30M
6/2022 Code Biotherapeutics Series A 0
5/2014 Lysosomal Therapeutics Seed Round 4.8M
12/2020 Atsena Therapeutics Series A 0
6/2020 Shattuck Labs Series B 0
12/2021 Trefoil Therapeutics Series A 0
7/2018 ORIG3N Series B 0
8/2010 TetraLogic Pharmaceuticals Series C 0
10/2013 G1 Therapeutics Series A 0
1/2015 Clinipace Private Equity Round 0
2/2015 G1 Therapeutics Series B 0
9/2018 PhaseBio Pharmaceuticals Series D 0
4/2023 Aer Therapeutics Series A 0
5/2023 Myeloid Therapeutics Series B 0
12/2022 Cardiosense Series A 0
10/2009 Embrella Cardiovascular Series B 1.6M
7/2019 Trefoil Therapeutics Series A 0
6/2021 Veralox Therapeutics Series A 0
3/2018 Wildflower Health Series C 8M
3/2021 Boston Immune Technologies &a; Therapeutics Series A 10M
4/2017 NeuroTronik Series B 0
7/2001 Empliant Venture Round 500k
2/2022 Huma.AI Series A 0
3/2015 GrayBug Series A 1.7M
2/2015 ORIG3N Venture Round 3.1M
7/2020 Altis Biosystems Seed Round 0
12/2020 Vigil Neuroscience Series A 50M
3/2017 Bivarus Series B 0
3/2018 Clinipace Venture Round 0
6/2021 Standard Bariatrics Series B 35M
1/2018 NurseGrid Venture Round 5.7M
12/2017 Qvella Corporation Series B 0
3/2019 Qvella Corporation Venture Round -
5/2023 Myeloid Therapeutics Series A 0
8/2022 RapidPulse Series A 0
3/2022 Wildflower Health Venture Round 0
6/2021 RapidPulse Series A 0
10/2007 PhaseBio Pharmaceuticals Venture Round 6.6M
12/2015 ORIG3N Series A 0
2/2013 Clearside Biomedical Series A 7.9M
6/2019 Artizan Biosciences Series A 0
10/2019 410 Medical Series A 8M
9/2014 Clearside Biomedical Series B 16M
4/2017 MATI Energy Series A 2.5M
7/2012 Coferon Series B 12M
10/2017 Ribometrix Seed Round 7.5M
6/2017 ORIG3N Venture Round 0
3/2021 StrideBio Series B 0
3/2018 Elligo Health Research Series B 0
10/2013 Sideris Pharmaceuticals Series A 32M
6/2015 Wildflower Health Equity 5M
3/2021 Artizan Biosciences Series A 0
8/2015 Medfusion Venture Round 3M
5/2016 G1 Therapeutics Series C 0
4/2018 Standard Bariatrics Series A 0
7/2020 CVRx Private Equity Round 0
5/2023 Myeloid Therapeutics Series A 0
5/2023 Ten63 Therapeutics Series A 0
4/2023 Aer Therapeutics Series A 0
4/2023 Mercy BioAnalytics Series A 0
12/2022 Cardiosense Series A 0
11/2022 410 Medical Series B 0
11/2022 Boomerang Medical Series A 0
8/2022 RapidPulse Series A 0
6/2022 Code Biotherapeutics Series A 0
3/2022 Wildflower Health Venture Round 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research
CoBee's Logo
Copyright © CoBee 2022. All Rights Reserved.